TG Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TG Therapeutics, Inc. on July 16, 2013, covering events that occurred on July 12, 2013. The filing addresses amendments to the compensatory arrangements for the company's Chief Executive Officer and Chief Financial Officer.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on executive compensation adjustments.
Material Changes
The Board of Directors approved amendments to the Restricted Stock Agreements for Michael S. Weiss (CEO) and Sean A. Power (CFO). The material change involves the vesting schedule for restricted stock previously tied solely to the company achieving a $300 million market capitalization. The new terms state that vesting will occur on the later of: (a) the date the company achieves a $300 million market capitalization, or (b) December 15, 2014.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies beyond the specific terms of the stock agreement amendments. No unusual items were reported.
Key Facts for Investor Verification
- The vesting trigger for CEO and CFO restricted stock now includes a time-based fallback date of December 15, 2014, if the $300 million market cap target is not met by then.
- The original market capitalization target of $300 million remains a condition for vesting.
- All other material terms of the original May 16, 2012 agreements remain unchanged.
- The filing does not provide current market capitalization or financial performance data.